Researchers report that complement immune proteins can redirect cancer-targeted nanoparticles to immune-cell uptake instead of delivering payloads to ovarian tumors. The study highlights an immune-system “decoy” mechanism that may help explain why some targeted nanomedicine strategies underperform in vivo. In the reported experiments, complement activation increased the capture of nanoparticles by immune cells, effectively reducing tumor accumulation. The finding underscores that targeting ligands alone may not be sufficient if opsonization by complement dominates the in vivo biodistribution. For translational nanomedicine programs, the work adds an actionable design constraint: minimizing complement engagement or engineering around it to preserve tumor delivery efficacy.
Get the Daily Brief